Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis, By Molecule(Pharmaceuticals, Biopharmaceuticals), By Sales Channel(Prescription, Over-the-counter (OTC)), By Region - Industry Forecast 2025-2032

Rheumatoid Arthritis Drugs Market size was valued at USD 25.01 Billion in 2023 and is poised to grow from USD 26.49 Billion in 2024 to USD 42 Billion by 2032, growing at a CAGR of 5.93% during the forecast period (2025-2032).

Major factors driving the growth of the market are increasing cases of arthritis as well as other joint complications. In addition to the increasing prevalence of rheumatoid arthritis and rising demand for its drugs, several other factors are contributing to the global rheumatoid arthritis drugs market growth. The expiration of patents and the emergence of biosimilars; the geriatric population; the rising use of conventional DMARDs; and the government initiatives targeted towards improving public awareness regarding the signs and symptoms of rheumatoid arthritis. The global rheumatoid arthritis drugs market has grown because of government efforts to investigate novel rheumatoid arthritis treatments. 

By enlisting the aid of significant industry players, the government is assisting in the expansion of the global market for rheumatoid arthritis treatments. As a result of increased awareness of rheumatoid arthritis drugs, increased research into them, growing healthcare reform, and increased use, more patients are taking them. Another factor driving the sector ahead is the ageing population and the corresponding rise in demand for DMARDs. This patient group is more likely to benefit therapeutically from a combination of biologics and disease-modifying antirheumatic medications. As a result, combination therapies that offer synergistic benefits are becoming more popular in the global rheumatoid arthritis drugs market. 

US Rheumatoid Arthritis Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.